Patents by Inventor Rita Slaaby

Rita Slaaby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Acylated Insulin Analogues and Uses Thereof
    Publication number: 20210094999
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 1, 2021
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Acylated insulin analogues and uses thereof
    Patent number: 10919949
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 16, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Novel Acylated Insulin Analogues and Uses Thereof
    Publication number: 20190194285
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Application
    Filed: August 16, 2018
    Publication date: June 27, 2019
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Process for preparing FGF21 with low degree of O-glycosylation
    Patent number: 9120871
    Abstract: Expression of FGF21 in a S. cerevisiae pmt2 knock out strain reduces the O-glycosylation significantly and does not decrease the expression level. Expression in mkc7 knock out strain can decrease degradation of FGF21 and analogues thereof. Point mutations at position R17 and R36 can decrease degradation of FGF21 and analogues thereof when they are expressed in yeast.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 1, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Rita Slaaby, Inger Lautrup-Larsen
  • PROCESS FOR PREPARING FGF21 WITH LOW DEGREE OF O-GLYCOSYLATION
    Publication number: 20130005951
    Abstract: Expression of FGF21 in a S. cerevisiae pmt2 knock out strain reduces the O-glycosylation significantly and does not decrease the expression level. Expression in mkc7 knock out strain can decrease degradation of FGF21 and analogues thereof. Point mutations at position R17 and R36 can decrease degradation of FGF21 and analogues thereof when they are expressed in yeast.
    Type: Application
    Filed: January 20, 2011
    Publication date: January 3, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Rita Slaaby, Inger Lautrup-Larsen
  • FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
    Publication number: 20100216715
    Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
    Type: Application
    Filed: January 22, 2010
    Publication date: August 26, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Jishu Wang, Kílían Waldemar Conde-Frieboes, Kristían Sass Bak-Jensen, Henning Thøgersen, Helle Wöldike, Peter Kresten Nielsen, Rita Slaaby, Xujia Zhang, Birgit Wieczorek